These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

996 related articles for article (PubMed ID: 17689146)

  • 21. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
    Thancharoen O; Limwattananon C; Waleekhachonloet O; Rattanachotphanit T; Limwattananon P; Limpawattana P
    Drugs Aging; 2019 May; 36(5):435-452. PubMed ID: 30937879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia.
    Wong CL; Bansback N; Lee PE; Anis AH
    Can J Neurol Sci; 2009 Nov; 36(6):735-9. PubMed ID: 19960752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Memantine for dementia.
    Areosa SA; Sherriff F
    Cochrane Database Syst Rev; 2003; (3):CD003154. PubMed ID: 12917950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
    Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Efficacy and Acceptability of Cholinesterase Inhibitors and Memantine Based on Dosage in Patients with Vascular Cognitive Impairment: A Network Meta-analysis.
    Shi X; Ren G; Cui Y; Xu Z
    Curr Alzheimer Res; 2022; 19(2):133-145. PubMed ID: 35048806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Medical treatment of Alzheimer's disease].
    Johannsen P
    Ugeskr Laeger; 2006 Oct; 168(40):3424-9. PubMed ID: 17032609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis.
    Tricco AC; Soobiah C; Berliner S; Ho JM; Ng CH; Ashoor HM; Chen MH; Hemmelgarn B; Straus SE
    CMAJ; 2013 Nov; 185(16):1393-401. PubMed ID: 24043661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
    Cumbo E; Ligori LD
    J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rivastigmine for Alzheimer's disease.
    Birks JS; Grimley Evans J
    Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug therapy of dementia in elderly patients. A review.
    Olsen CE; Poulsen HD; Lublin HK
    Nord J Psychiatry; 2005; 59(2):71-7. PubMed ID: 16195103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model.
    Van Dam D; Abramowski D; Staufenbiel M; De Deyn PP
    Psychopharmacology (Berl); 2005 Jun; 180(1):177-90. PubMed ID: 15654502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rivastigmine for Alzheimer's disease.
    Birks J; Grimley Evans J; Iakovidou V; Tsolaki M; Holt FE
    Cochrane Database Syst Rev; 2009 Apr; (2):CD001191. PubMed ID: 19370562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative efficacy and safety of cognitive enhancers for treating vascular cognitive impairment: systematic review and Bayesian network meta-analysis.
    Jin BR; Liu HY
    Neural Regen Res; 2019 May; 14(5):805-816. PubMed ID: 30688266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
    Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
    CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Cholinesterase Inhibitors in Vascular Dementia: An Updated Meta-Analysis.
    Chen YD; Zhang J; Wang Y; Yuan JL; Hu WL
    Eur Neurol; 2016; 75(3-4):132-41. PubMed ID: 26918649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.
    Thompson S; Lanctôt KL; Herrmann N
    Expert Opin Drug Saf; 2004 Sep; 3(5):425-40. PubMed ID: 15335298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of antidementia agents in vascular dementia: beyond Alzheimer disease.
    Farlow MR
    Mayo Clin Proc; 2006 Oct; 81(10):1350-8. PubMed ID: 17036561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drugs for cognitive loss and dementia.
    Treat Guidel Med Lett; 2013 Oct; 11(134):95-100; quiz 1 p following p100.. PubMed ID: 24081314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
    Noetzli M; Eap CB
    Clin Pharmacokinet; 2013 Apr; 52(4):225-41. PubMed ID: 23408070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.